Pfizer Recalls Lots of Ambaro (valsartan and amlodipine besylate salt) for its Carcinogenic Effects in Japan

Shots:

• The voluntary Class I recall of Ambaro is due to presence of trace amounts of N-nitrosodiethylamine (NDEA) & N-nitrosodimethylamine (NDMA) in marketed b/w 3 Dec,2018 to 23 Jan,2019
• The recall is for no. of 763,000 tablets, manufactured in April to July 2018 which contained cancer causing substance, also examined by WHO
• Additionally, Teva and Mylan initiated their recalls in Jan,2019 and Dec,2018 respectively for valsartan lots used as anti-hypertensive medication

Click here to read full press release/ article | Ref: Pfizer | Image: Wall Street Journal